Breast cancer survivors are at risk of developing breast cancer-related lymphedema (BCRL) after surgical treatment, which may have a negative effect on quality of life. The purpose of this study was to investigate the clinical role of bioelectrical impedance analysis (BIA) and the relationship between the development of BCRL in breast cancer survivors who have undergone axillary surgery.
Methods
A total of 228 patients with breast cancer were enrolled in the study between May 2016 and January 2017. BCRL was assessed by measuring the circumference of both arms at 15 cm below the acromion process and the olecranon process. Patients were classified as BCRL (n = 22) and non-BCRL (n = 206) based on the difference of the arm circumference of 2 cm. Data including lymphedema, anthropometry, BIA measurements, food frequency questionnaire, type of surgery, total number of dissected lymph nodes, and post-operative treatment were collected.
Results
Of the breast cancer survivors, 10.4% had BCRL by the definition. The BCRL group contained 22 patients, while the non-BCRL group contained 206 patients. Compared to the non-BCRL group, the BCRL group had a higher body mass index, a larger percentage of ideal body weight, more dissected lymph nodes, and higher single frequency BIA (SFBIA) ratio (P = 0.027, P = 0.031, P < 0.001, and P < 0.001, respectively). The SFBIA ratio provided 63.64% sensitivity and 95.15% specificity in estimating the risk of BCRL.
Conclusion
Our data provides evidence to support that the use of SFBIA ratio can serve as an alternative method to monitor and/or diagnose BCRL.
Trial registration
This trial was retrospectively registered at Clinicaltrials.gov identifier (NCT03391206) on the 5 January 2018.
Hinweise
Co-First author: Sung Mook Lim; Yujin Han
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Background
Lymphedema can be clinically diagnosed based on the swelling of limbs. However, definitive diagnosis of lymphedema is difficult, because most would suggest that lymphatic dysfunction imaged by lymphoscintigraphy or indocyanine green lymphography is required. The clinical diagnosis of lymphedema includes the observation that the bilateral difference in limb circumference is 2 cm or more [1], the difference of pre and post operation in volume of the limb is more than 200 ml [2], or the bilateral difference in volume of the limb change is 10% [3]. Because of differences in diagnostic criteria in these measurement methods, the definitive diagnosis is difficult. In addition, ultrasound, computed tomography, and magnetic resonance imaging are used to diagnose lymphedema. The ultrasound can measure volumetric and structural changes in the dermis, subcutaneous layer, and muscle, but information on the truncal anatomy of the lymphatic system can not be confirmed [4]. The computed tomography can detect thickening of the skin and subcutaneous compartment, and thickened perimuscular aponeurosis [4]. The magnetic resonance imaging can distinguish lymphedema, lipedema, and phlebedema, and can confirm the circumferential measurement edema, thickened dermis, and increased subcutaneous compartment [4, 5].
The arm circumference measurement is a commonly utilized clinical diagnosis method [6]. The circumference of both arms at 15 cm below the acromion process and the olecranon process is measured, and the circumference values of the affected arm and unaffected arm are compared [6, 7]. However, with this method there is no standardized reference point and low sensitivity. The lack of evidence-based diagnostic criteria to define lymphedema has presented tremendous challenges in terms of diagnosis. Therefore, defining criteria for the early detection and treatment of lymphedema is important [8].
Anzeige
Recently, several researchers have used bioelectrical impedance analysis (BIA) to diagnose lymphedema [9‐14]. This method is highly sensitive, can be used as a basis to establish standardized criteria, and can be used to measure extracellular space [9, 15, 16]. Bioelectrical impedance predicts body composition using differences in electric conductivity upon sending a minute current through the human body [17, 18]. In several studies, the single frequency bioelectrical impedance analysis (SFBIA) of the two arms obtained using bioelectrical impedance measurements was expressed as the ratio of the values of the operated and non-operated arms [10, 19]. However, this method has not been validated as a diagnostic tool. It is therefore necessary to study this method further to establish it as an efficient diagnostic means.
The purpose of this study is to determine diagnostic accuracy of bioelectrical impedance as a diagnostic method based on the presence of lymphedema compared with circumference measurements. In addition, the aim is to identify risk factors to help prevent lymphedema for breast cancer survivors.
Methods
Study design and subjects
This prospective study was conducted at Severance Hospital in Korea from May 2016 to January 2017 and involved female unilateral breast cancer survivors aged 20 or older who underwent surgery at least six months prior to selection. Patients with bilateral breast cancer, male breast cancer, recurrent breast cancer, previous ipsilateral axillary surgery, and previous radiotherapy were excluded. This study was approved by the Institutional Review Board of Severance Hospital (IRB Number: 4–2016-0149). All patients participated voluntarily in the study and provided written informed consent. All subjects underwent BIA, body measurements and semi-quantitative food frequency questionnaire for the Korean Genome Epidemiologic Study [20].
A total of 250 patients were recruited. A total of 228 patients were finally enrolled in the study. (Clinicaltrials.gov identifier: NCT03391206). Of the patients who were excluded, 10 had bilateral breast cancer, 10 had poor medical records, and two did not have bioelectrical impedance measured (Fig. 1). The presence or absence of lymphedema was assessed in 228 patients based on circumference measurements [6]. Arm circumference measurements were examined using a method that was described in the previous study definition [21]. The circumference of both arms at 15 cm below the acromion and the olecranon process was measured, and the measured values of the affected and unaffected arm were compared. Patients were classified as BCRL group (n = 22) with a difference more than or equal to 2 cm and non-BCRL group (n = 206) with a difference less than 2 cm.
Fig. 1
Flowchart illustrating the classification of the study participants in breast cancer survivors
×
Anzeige
Anthropometric parameter and body composition measurements
Body height was measured using an automatic extension meter. Body composition analysis was performed with an Inbody 720 composition analyzer (Biospace, Seoul, South Korea). Before assessment, participants were instructed to avoid excessive fluid intake, alcohol ingestion and heavy physical activity. Subjects were asked to remove anything metal and to stand barefoot on the metal footpads while loosely holding the handgrips. The results were automatically input into the system. Body weight, fat mass, body mass index (BMI), the waist-hip ratio (WHR), percent of ideal body weight (PIBW), extracellular water (ECW), total body water (TBW), and SFBIA were measured using BIA. SFBIA values were noted for both upper extremities at 1 kHz and 5 kHz. The SFBIA ratio was calculated as the ratio of the values of the affected to unaffected arms [14]. The SFBIA ratio was used to assess lymphedema.
BMI, PIBW, and SFBIA ratio were calculated as follows;
BMI
BMI = body weight in kilograms / (height in meters)2.
PIBW
PIBW = actual weight / ideal body weight*× 100.
*ideal body weight = (height in meters)2xideal BMI#.
#ideal BMI = female; 21 kg/m2, male; 20 kg/m2.
SFBIA ratio
SFBIA ratio = unaffected SFBIA / affected SFBIA.
Medical record collection
Clinicopathological information was obtained from the medical records of the participating women. Clinicopathological variables included surgery type (sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND)), number of dissected lymph nodes, and postoperative therapy such as chemotherapy, radiotherapy, hormone therapy, and target therapy.
Anzeige
Statistical analysis
The variables used in this study were anthropometric values, the SFBIA value, the intake of nutrients, activity level, healthy functional foods, surgical methods, the number of removed lymph nodes, and treatment methods. The results are described as mean and standard deviation. The relationship between variables in the non-BCRL and BCRL groups was analyzed. The chi-squared test or Fishers exact test and independent sample t-test or Mann-Whitney U test were used for the analyses. The reported p-values are two-sided and were considered statistically significant at 0.05 or less. All data analyses were performed using IBM SPSS Statistics version 23.0 for Windows (IBM Corp., Armonk, NY, USA).
Results
Subject characteristics
Table 1 details the general characteristics of the study patients, who were classified according to axillary surgery type (SLNB or ALND) and the presence or absence of lymphedema (Non-BCRL or BCRL). No significant differences between the non-BCRL group and BCRL group were found in terms of age or physical activity level. The lymphedema of the operated site was significantly higher in the right side than in the left side. The number of lymph nodes removed was significantly higher in the BCRL than in the non-BCRL, but this difference was not observed when the subjects were divided according to surgery type (SLNB or ALND). The mean value of the acromion circumference difference was 2.69 ± 1.70 cm in the BCRL group. The arm circumference difference was larger in the lymphedema group with ALND than in the group with SLNB.
fSedentary: Most of the time is spent sitting in a static activity
gActive: Most of the time spent sitting, but lifestyle also includes standing work, commuting, buying things, housework, light exercise
hVery active: Strenuous work or highly active leisure
Anthropometry and bioelectrical impedance data
The anthropometric data including body weight, fat mass, BMI, body fat percentage (BFP), WHR, PIBW, ECW/TBW, and SFBIA ratio were compared between the non-BCRL and BCRL groups for each surgery type (Table 2). BMI was significantly higher in the BCRL group (P = 0.027). Obesity-related factors including body weight, fat mass, BFP, PIBW, and BMI were significantly higher in the BCRL group than in the non-BCRL group for SLNB patients, while there were no significant differences among the ALND patients.
Table 2
Analysis of BCRL and non- BCRL values through bioelectrical impedance analysis
SLNB
ALND
Total
(n = 148)
(n = 80)
(n = 228)
Non-BCRL
BCRL
P valuea
Non-BCRL
BCRL
P valueb
Non-BCRL
BCRL
P valueb
(n = 142)
(n = 6)
(n = 64)
(n = 16)
(n = 206)
(n = 22)
BW (kg)
59.4 ± 10.6
72.4 ± 12.0
0.009
59.1 ± 10.4
58.7 ± 6.7
0.878
59.3 ± 10.5
62.4 ± 10.2
0.183
FFM (kg)
39.3 ± 4.5
43.8 ± 4.4
0.052
39.3 ± 4.7
38.4 ± 4.2
0.494
40.3 ± 14.6
39.9 ± 4.8
0.904
FM (kg)
20.1 ± 7.7
28.6 ± 8.0
0.016
19.8 ± 7.5
20.3 ± 4.8
0.816
20.0 ± 7.6
22.5 ± 6.8
0.131
BMI (kg/m2)c
23.8 ± 4.2
28.4 ± 4.5
0.011
23.6 ± 4.0
24.7 ± 2.7
0.275
23.7 ± 4.1
25.7 ± 3.6
0.027
BFP (%)
32.8 ± 7.2
38.8 ± 5.1
0.034
32.8 ± 6.5
34.2 ± 5.6
0.421
32.8 ± 7.0
35.5 ± 5.8
0.084
WHR
0.87 ± 0.06
0.89 ± 0.05
0.180
0.86 ± 0.05
0.89 ± 0.05
0.180
0.87 ± 0.06
0.89 ± 0.05
0.088
PIBWd
112.6 ± 20.0
134.7 ± 21.8
0.012
111.6 ± 19.0
116.9 ± 13.1
0.296
112.3 ± 19.6
121.7 ± 17.3
0.031
ECW/TBW
0.39 ± 0.01
0.39 ± 0.01
0.312
0.39 ± 0.01
0.39 ± 0.01
0.168
0.39 ± 0.01
0.39 ± 0.01
0.068
SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection, non-BCRL non-breast cancer-related lymphedema, BCRL breast cancer-related lymphedema, BW body weight, FFM fat free mass, FM fat mass, BMI body mass index, BFP body fat percentage, WHR waist-Hip ratio, PIBW percent of ideal body weight, ECW/TBW extracellular water/total body water
Values are mean ± standard deviation
aP values of differences between means were calculated using the Mann-Whitney U test
bP values of differences between means were calculated using an independent sample t-test
cBody mass index(BMI) was calculated body weight in kilograms/(height in meters)2
dPercent of ideal body weight(PIBW) was determined by the equation actual weight (kg)/ideal body weight (kg) × 100
Diagnosis of lymphedema using SFBIA ratio
Table 3 summarizes SFBIA ratios calculated from the ratio of the values of the operated and non-operated arms. The SFBIA values of the bioelectrical impedance were measured at 1 kHz and 5 kHz. The 1 kHz SFBIA ratio of the BCRL and non-BCRL groups was 1.145 ± 0.234 and 0.996 ± 0.039 (p < 0.001), respectively. The 5 kHz SFBIA ratio was significantly higher in the BCRL group than in the non-BCRL group (p < 0.001). Regarding the SFBIA ratio, a significant difference was observed between the non-BCRL and BCRL groups for ALND patients, but there was a tendency without significance for SLNB patients.
Table 3
SFBIA ratioa of breast cancer survivors according to lymphedema
SLNB
ALND
Total
(n = 148)
(n = 80)
(n = 228)
Non-BCRL
BCRL
P valueb
Non-BCRL
BCRL
P valuec
Non-BCRL
BCRL
P valuec
(n = 142)
(n = 6)
(n = 64)
(n = 16)
(n = 206)
(n = 22)
1 kHz
0.991 ± 0.039
1.013 ± 0.045
0.183
1.006 ± 0.036
1.194 ± 0.257
< 0.001
0.996 ± 0.039
1.145 ± 0.234
< 0.001
5 kHz
0.990 ± 0.036
1.016 ± 0.037
0.075
1.004 ± 0.037
1.177 ± 0.250
< 0.001
0.994 ± 0.037
1.133 ± 0.225
< 0.001
SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection, non-BCRL non-breast cancer-related lymphedema, BCRL breast cancer-related lymphedema, SFBIA ratio single-frequency bioelectrical impedance analysis ratio
Values are mean ± standard deviation
aSingle-frequency bioelectrical impedance analysis(SFBIA) ratio of the affected to unaffected side were calculated
bP values of differences between means were calculated using the Mann-Whitney U test
cP values of differences between means were calculated using an independent sample t-test
Anzeige
Receiver operating characteristic curve (ROC) analyses were performed in order to evaluate diagnostic ability of SFBIA ratio using the1 kHz and 5 kHz SFBIA ratios. Figure 2 shows the ROC curve in 1 kHz and 5 kHz. Our SFBIA ratio cut-off value are 1.049 and 1.047, respectively. Area under the curve of 5 kHz SFBIA ratio was higher than that of 1 kHz (5 kHz; 0.77, 1 kHz; 0.74). The 5 kHz SFBIA ratio showed better performance as a diagnostic tool compared to 1 kHz SFBIA ratio with an area under the curve of 0.77 (95% CI: 0.63–0.90). The 5 kHz SFBIA ratio values were used as criteria for determining the occurrence of lymphedema in each patient. The analysis of diagnostic accuracy of the 5 kHz SFBIA showed specificity of 95.15%, sensitivity of 63.64%, positive predictive value of 58.33%, and negative predictive value of 96.08%.
Fig. 2
ROC curve of the 1 kHz and 5 kHz SFBIA ratio value. After the breast cancer surgery, the 1 kHz and 5 kHz SFBIA ratio of the survivors showed the good test performance to detect lymphedema with an area under the curve of 0.74 (95% CI: 0.59–0.89) and 0.77 (95% CI: 0.63–0.90), respectively. The 1 kHz and 5 kHz SFBIA ratio were effective predictors of post–BCRL(p = 0.000, p = 0.000)
×
Discussion
Early prevention and detection of postoperative lymphedema complications in breast cancer patients is important for quality of life. Our data provided evidence to support the use of the SFBIA ratio by BIA in lymphedema in breast cancer survivors. In addition, right axillary surgery was suggested to be a risk factor associated with lymphedema. Lymphedema was more common in patients with the right axillary procedure than those with the left. This may be due to the fact that right handed people are more common and have more axillary activity on the right side. Additionally, the number of dissected lymph nodes [22‐25], obesity [23, 24, 26, 27], and surgery type [22, 24, 25] were risk factors for lymphedema. It was concordant with previous study [22‐27].
In this study, BCRL was determined based on more than a 2 cm difference in the circumference, as measured 15 cm below the olecranon, or acromion process, of the arm not affected by the operation relative to the circumference of the arm on the same side as the operation [7, 28, 29]. Limitations include potential errors in the measurements and the fact that diagnosis is not possible until clinical symptoms are seen. More precise techniques including ultrasound, computed tomography, magnetic resonance imaging, lymphoscintigraphy and other volumetric measurement can enhance the diagnosis of lymphedema. Further studies that evaluate the comparison these techniques and BIA are needed.
BIA is designed to measure edema as an extremely small electrical current passes through extracellular fluid [9]. This technique distinguishes extracellular fluid from total limb volume [9, 30]. In the presence of lymphedema, the SFBIA ratio [10] is related to the accumulation of extracellular fluid [31]. Our results show that the SFBIA ratio is larger at 5 kHz than at 1 kHz. BIA had good performance in terms of specificity (95.15%) and negative predictive value (96.08%). A diagnostic tool with a high specificity is more useful for ‘judging’ a disease when a person is positive and the negative predictive value can be used that the probability of not having disease given a negative diagnosis [32]. These values indicate that BIA can be used as a method of monitoring and diagnosing lymphedema. Previous studies have reported that early surveillance for risk of lymphedema using bioimpedance spectroscopy with early intervention with compression garments can reduce the incidence of more advanced lymphedema [11, 12]. Our cut-off value of the SFBIA ratio for diagnosing lymphedema should be validated in further studies. The usefulness of early detection through the SFBIA ratio is necessary to be evaluated as well.
Anzeige
Well-known risk factors for lymphedema include the surgery type [22, 24, 25] and the number of dissected lymph nodes [22‐25]. Similarly, our study also demonstrated that the higher the number of lymph nodes removed in the ALND subjects, the higher the incidence of lymphedema. However, these were not observed for the SLNB because the number of lymph nodes removed is too small to affect the risk of lymphedema in these subjects. Overall, on average our SLNB subjects had less than 5 lymph nodes removed whereas the ALND had 16 to 20 lymph nodes removed. Thus, surgery type associated with high lymph node removal is likely to increase the risk of lymphedema as reported previously [22‐25].
Obesity-related indicators in breast cancer patients increase the risk of developing lymphedema complications [26, 33, 34]. Our data investigated the relationship between the incidence of lymphedema and the variables related to anthropometric measurements and type of surgery. The BMI and PIBW of the subjects were significantly higher in the presence of lymphedema. In particular, body fat percentage, BMI, and PIBW were significantly different in patients who underwent SLNB. These findings suggest that the occurrence of lymphedema is associated with obesity and that patients who undergo SLNB procedures should pay attention to maintaining normal weight. There was no significant difference of obesity-related indicators between BCRL and non-BCRL in the patients with ALND. Our results were different from the studies conducted on Westerners. The association between BMI and lymphedema volume in patients with ALND was observed [35, 36]. The difference between ours and previous studies may be due to difference of study population, a race, culture, lifestyle, and dietary differences between Westerners and Asians. Further research is needed to understand the factors behind these differences.
The lymphedema of our subjects was confirmed by the difference in limb circumference of 2 cm of both sides. This confirmed the lymphedema of the arm, but not the lymphedema that appeared at other sites. Therefore, the diagnosis of more detailed lymphedema will establish an accurate standard of the SFBIA ratio. Nevertheless, our study confirmed the cut-off value of the SFBIA ratio for the determination of lymphedema through 228 subjects and confirmed the sensitivity and specificity. Our findings have shown the possibility of SFBIA ratio as a useful tool for the diagnosis and management of lymphedema in breast cancer survivors. In addition, we found that there was a significant correlation between lymphedema and obesity in patients who underwent SLNB, but not in patients who underwent ALND.
Conclusion
The SFBIA ratio obtained using BIA can be an alternative method for monitoring and/or diagnosing BCRL. The BIA had a sensitivity of 63.64% and a specificity of 95.15% in predicting BCRL. In addition, number of dissected lymph nodes, operation site, surgery type, obesity, and the SFBIA ratio are significantly associated with the occurrence of lymphedema.
Acknowledgements
The authors thank the patients who participated in this study.
Ethics approval and consent to participate
This study was approved by the Institutional Review Board of Severance Hospital (IRB number 4–2016-0149), and this trial is registered with Clinicaltrials.gov identifier, NCT03391206. All participants participated voluntarily and completed a written informed consent.
Consent for publication
Not Applicable.
Competing interests
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.
Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.
Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.
Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
